Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease
Background: Increased iron deposition in nigrosome as assessed by susceptibility-weighted imaging (SWI) is involved in the pathogenesis of Parkinson’s disease (PD). This study investigated the effects of antiparkinson drugs on iron deposition in the nigrosome of PD patients.Methods: Based on the ret...
| Main Authors: | , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2022-07-01
|
| Series: | Frontiers in Molecular Biosciences |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fmolb.2022.908298/full |
| _version_ | 1828775671615193088 |
|---|---|
| author | Mengdi Wang Hongxia Wang Jing Wang Shujun Lu Chen Li Xiaofei Zhong Nan Wang Ruli Ge Qi Zheng Jinbo Chen Hongcai Wang |
| author_facet | Mengdi Wang Hongxia Wang Jing Wang Shujun Lu Chen Li Xiaofei Zhong Nan Wang Ruli Ge Qi Zheng Jinbo Chen Hongcai Wang |
| author_sort | Mengdi Wang |
| collection | DOAJ |
| description | Background: Increased iron deposition in nigrosome as assessed by susceptibility-weighted imaging (SWI) is involved in the pathogenesis of Parkinson’s disease (PD). This study investigated the effects of antiparkinson drugs on iron deposition in the nigrosome of PD patients.Methods: Based on the retrospective analysis of clinical data, alterations in iron deposition in the substantia nigra were investigated in 51 PD patients across different types of therapies and in nine Parkinson-plus syndrome patients. The Movement Disorder Society revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part Ⅲ/Ⅳ (UPDRS Ⅲ/Ⅳ) was utilized to evaluate motor function and complications. SWI (slice = 0.6 mm) was used to detect iron deposition in the nigrosome and substantia nigra. Nigrosome loss was scored on a 1-point nigrosome visibility scale. Visual assessment of dorsolateral nigral hyperintensity (DNH) was separately performed for each side of the nigrosome with SWI.Results: Increased UPDRS Ⅲ scores were correlated with low nigrosome scores based on correlation analysis at a disease duration of 6–12 months (r = −0.8420). The loss of the nigrosome on SWI was clearly inhibited in PD patients with a 3–5-year duration of administration of antiparkinson medications compared with no treatment. Decreased UPDRS Ⅲ scores and increased nigrosome scores were observed in the regular treatment of PD patients with a 6–7-year disease duration. For patients with Parkinson-plus syndromes, such as multiple system atrophy, iron accumulation was apparent in the corpus striatum and substantia nigra compared with that for patients with progressive supranuclear palsy.Conclusions: Early and regular treatment with antiparkinson drugs not only alleviates the chance of PD disability but also prevents the loss of DNH, namely, iron accumulation in the nigrosome. |
| first_indexed | 2024-12-11T15:44:33Z |
| format | Article |
| id | doaj.art-6affb00986414ce2b04a4a846e00f3c6 |
| institution | Directory Open Access Journal |
| issn | 2296-889X |
| language | English |
| last_indexed | 2024-12-11T15:44:33Z |
| publishDate | 2022-07-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Molecular Biosciences |
| spelling | doaj.art-6affb00986414ce2b04a4a846e00f3c62022-12-22T00:59:44ZengFrontiers Media S.A.Frontiers in Molecular Biosciences2296-889X2022-07-01910.3389/fmolb.2022.908298908298Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s DiseaseMengdi Wang0Hongxia Wang1Jing Wang2Shujun Lu3Chen Li4Xiaofei Zhong5Nan Wang6Ruli Ge7Qi Zheng8Jinbo Chen9Hongcai Wang10Department of Neurology, Binzhou Medical University Hospital, Binzhou, ChinaDepartment of Radiology, Binzhou Medical University Hospital, Binzhou, ChinaDepartment of Radiology, Binzhou Medical University Hospital, Binzhou, ChinaDepartment of Neurology, Binzhou Medical University Hospital, Binzhou, ChinaMedical Research Center, Binzhou Medical University Hospital, Binzhou, ChinaDepartment of Radiology, Binzhou Medical University Hospital, Binzhou, ChinaMedical Research Center, Binzhou Medical University Hospital, Binzhou, ChinaDepartment of Neurology, Binzhou Medical University Hospital, Binzhou, ChinaDepartment of Neurology, Binzhou Medical University Hospital, Binzhou, ChinaDepartment of Neurology, Binzhou Medical University Hospital, Binzhou, ChinaDepartment of Neurology, Binzhou Medical University Hospital, Binzhou, ChinaBackground: Increased iron deposition in nigrosome as assessed by susceptibility-weighted imaging (SWI) is involved in the pathogenesis of Parkinson’s disease (PD). This study investigated the effects of antiparkinson drugs on iron deposition in the nigrosome of PD patients.Methods: Based on the retrospective analysis of clinical data, alterations in iron deposition in the substantia nigra were investigated in 51 PD patients across different types of therapies and in nine Parkinson-plus syndrome patients. The Movement Disorder Society revision of the Unified Parkinson’s Disease Rating Scale (MDS-UPDRS) Part Ⅲ/Ⅳ (UPDRS Ⅲ/Ⅳ) was utilized to evaluate motor function and complications. SWI (slice = 0.6 mm) was used to detect iron deposition in the nigrosome and substantia nigra. Nigrosome loss was scored on a 1-point nigrosome visibility scale. Visual assessment of dorsolateral nigral hyperintensity (DNH) was separately performed for each side of the nigrosome with SWI.Results: Increased UPDRS Ⅲ scores were correlated with low nigrosome scores based on correlation analysis at a disease duration of 6–12 months (r = −0.8420). The loss of the nigrosome on SWI was clearly inhibited in PD patients with a 3–5-year duration of administration of antiparkinson medications compared with no treatment. Decreased UPDRS Ⅲ scores and increased nigrosome scores were observed in the regular treatment of PD patients with a 6–7-year disease duration. For patients with Parkinson-plus syndromes, such as multiple system atrophy, iron accumulation was apparent in the corpus striatum and substantia nigra compared with that for patients with progressive supranuclear palsy.Conclusions: Early and regular treatment with antiparkinson drugs not only alleviates the chance of PD disability but also prevents the loss of DNH, namely, iron accumulation in the nigrosome.https://www.frontiersin.org/articles/10.3389/fmolb.2022.908298/fulliron accumulationnigrosomeParkinson’s diseaselevodopadorsolateral nigral hyperintensity |
| spellingShingle | Mengdi Wang Hongxia Wang Jing Wang Shujun Lu Chen Li Xiaofei Zhong Nan Wang Ruli Ge Qi Zheng Jinbo Chen Hongcai Wang Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease Frontiers in Molecular Biosciences iron accumulation nigrosome Parkinson’s disease levodopa dorsolateral nigral hyperintensity |
| title | Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease |
| title_full | Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease |
| title_fullStr | Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease |
| title_full_unstemmed | Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease |
| title_short | Modified Iron Deposition in Nigrosomes by Pharmacotherapy for the Management of Parkinson’s Disease |
| title_sort | modified iron deposition in nigrosomes by pharmacotherapy for the management of parkinson s disease |
| topic | iron accumulation nigrosome Parkinson’s disease levodopa dorsolateral nigral hyperintensity |
| url | https://www.frontiersin.org/articles/10.3389/fmolb.2022.908298/full |
| work_keys_str_mv | AT mengdiwang modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT hongxiawang modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT jingwang modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT shujunlu modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT chenli modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT xiaofeizhong modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT nanwang modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT rulige modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT qizheng modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT jinbochen modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease AT hongcaiwang modifiedirondepositioninnigrosomesbypharmacotherapyforthemanagementofparkinsonsdisease |